NewAmsterdam Pharma (NAMS) Total Current Liabilities (2021 - 2026)

NewAmsterdam Pharma (NAMS) has 6 years of Total Current Liabilities data on file, last reported at $67.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 64.79% year-over-year to $67.4 million; the trailing twelve-month figure through Mar 2026 stood at $67.4 million (up 64.79% YoY), and the FY2025 full-year result was $85.8 million, down 19.76% from the prior year.
• Total Current Liabilities declined to $67.4 million in Q1 2026, from $85.8 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $106.9 million in Q4 2024 to a low of $36.2 million in Q4 2022.
• A 5-year average of $55.8 million and a median of $47.6 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities surged 220.1% in 2022 and plunged 31.5% in 2025, its largest moves.
• Tracing NAMS's Total Current Liabilities over 5 years: stood at $36.2 million in 2022, then jumped by 37.92% to $49.9 million in 2023, then jumped by 114.28% to $106.9 million in 2024, then retreated by 19.76% to $85.8 million in 2025, then slipped by 21.41% to $67.4 million in 2026.
• Business Quant data shows NAMS's Total Current Liabilities at $67.4 million in Q1 2026, $85.8 million in Q4 2025, and $58.3 million in Q3 2025.